SCHEMBL25545956

SCHEMBL25545956

COc1ccc(-c2nc(Cl)sc2CCC(C)C)cc1Cl

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 3/20 0.39
MAPT P10636 3/20 0.38
LMNA P02545 2/20 0.38
SLC10A2 Q12908 1/20 0.38
ALDH1A1 P00352 1/20 0.38
PTGS2 P35354 1/20 0.37
ADORA2A P29274 1/20 0.37
ADORA1 P30542 1/20 0.37
KMO O15229 1/20 0.36
MEN1 O00255 5/20 0.36
KMT2A Q03164 5/20 0.36
POLB P06746 2/20 0.36
GAA P10253 1/20 0.35
S1PR1 P21453 1/20 0.35
S1PR3 Q99500 1/20 0.35
CTDSP1 Q9GZU7 1/20 0.35
PPARD Q03181 1/20 0.35
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25545938 0.90 DYRK1A (0.39) GRM2MAPTLMNASLC10A2ALDH1A1
SCHEMBL25545930 0.88 ALDH1A1 (0.41) GRM2MAPTLMNASLC10A2ALDH1A1
SCHEMBL25545544 0.88 S1PR4 (0.37) MAPTLMNAALDH1A1PTGS2
SCHEMBL25546328 0.87 S1PR1 (0.43) GRM2MAPTLMNASLC10A2ALDH1A1
SCHEMBL25545935 0.86 PAX8 (0.38) GRM2MAPTLMNASLC10A2ALDH1A1
SCHEMBL25546020 0.81 TRPV1 (0.43) MAPTLMNASLC10A2ALDH1A1MEN1
SCHEMBL30271624 0.81 ADORA2A (0.40) GRM2MAPTLMNASLC10A2PTGS2
SCHEMBL25545547 0.79 AAK1 (0.36) ALDH1A1PTGS2
SCHEMBL25545941 0.79 LMNA (0.48) MAPTLMNAALDH1A1MEN1KMT2A
SCHEMBL25545932 0.78 FBP1 (0.44) GRM2MAPTLMNAALDH1A1KMO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 US disclosed
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 GRM2 3571/4885MAPT 2231/4885LMNA 2647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.